ES2185237T3 - 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica. - Google Patents
1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica.Info
- Publication number
- ES2185237T3 ES2185237T3 ES98959052T ES98959052T ES2185237T3 ES 2185237 T3 ES2185237 T3 ES 2185237T3 ES 98959052 T ES98959052 T ES 98959052T ES 98959052 T ES98959052 T ES 98959052T ES 2185237 T3 ES2185237 T3 ES 2185237T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- generally associated
- transmission
- glutamatergical
- asamantil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000005540 biological transmission Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000005856 abnormality Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/16—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Soy Sauces And Products Related Thereto (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Utilización de un compuesto de fórmula (1):**Fórmula** en la que X es una cadena de alquileno sustituido o no sustituido que contiene 0, 1, 2, 3 ó 4 átomos de carbono, donde uno o más átomos de carbono de la cadena X puede estar sustituido independientemente por grupo(s) sustituyente(s) seleccionado(s) de alquilo y arilo; R1, R2 y R3 son seleccionados independientemente de hidrógeno, alquilo y arilo; R4, R5 y R6 son seleccionados independientemente de hidrógeno, alquilo, arilo, halógeno y alcoxi; y sales del mismo farmacéuticamente aceptables; donde dicho grupo alquilo se define como un radical hidrocarbilo ramificado o no ramificado, cíclico o acíclico, saturado o insaturado, y dicho grupo arilo se define como un grupo aromático o heteroaromático, en la fabricación de un medicamento para ser utilizado en el tratamiento de una condición asociada generalmente con anormalidades en la transmisión glutamatérgica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9726388.3A GB9726388D0 (en) | 1997-12-12 | 1997-12-12 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2185237T3 true ES2185237T3 (es) | 2003-04-16 |
Family
ID=10823580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98959052T Expired - Lifetime ES2185237T3 (es) | 1997-12-12 | 1998-12-11 | 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica. |
Country Status (9)
Country | Link |
---|---|
US (2) | US6500866B1 (es) |
EP (1) | EP1037874B1 (es) |
JP (1) | JP2002508350A (es) |
AT (1) | ATE225768T1 (es) |
AU (1) | AU1498299A (es) |
DE (1) | DE69808669T2 (es) |
ES (1) | ES2185237T3 (es) |
GB (1) | GB9726388D0 (es) |
WO (1) | WO1999031051A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002519373A (ja) | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
GB9901691D0 (en) | 1999-01-26 | 1999-03-17 | Cerebrus Ltd | Chemical compounds |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
ITTO20030668A1 (it) | 2003-09-02 | 2005-03-03 | Rotta Res Lab S P A O Ra Rottapharm | Derivati dell'adamantano dotati di attivita' neuroprotettiva, antidepressiva e anti-ischemica e procedimento per la loro preparazione. |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
HUP0401523A3 (en) * | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE151447C (es) | ||||
BE795381A (fr) * | 1972-02-15 | 1973-08-13 | Sandoz Sa | Derives de l'adamaniane |
JPS5246949B2 (es) * | 1973-10-19 | 1977-11-29 | ||
DD151447A1 (de) * | 1980-06-18 | 1981-10-21 | Heinz Paul | Verfahren zur herstellung von amidinen und deren salzen |
WO1992004054A1 (en) * | 1990-08-30 | 1992-03-19 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY, PORTLAND, OREGON, and THE UNIVERSITY OF OREGON, EUGENE, OREGON, Johnson Hall, University of Oregon | Substituted amidines having high binding to the sigma receptor and the use thereof |
US5677349A (en) * | 1995-04-27 | 1997-10-14 | Gilad; Gad M. | Agmatine for the treatment of neurotrauma and neurodegenerative diseases |
-
1997
- 1997-12-12 GB GBGB9726388.3A patent/GB9726388D0/en not_active Ceased
-
1998
- 1998-12-11 JP JP2000538980A patent/JP2002508350A/ja not_active Withdrawn
- 1998-12-11 EP EP98959052A patent/EP1037874B1/en not_active Expired - Lifetime
- 1998-12-11 ES ES98959052T patent/ES2185237T3/es not_active Expired - Lifetime
- 1998-12-11 WO PCT/GB1998/003715 patent/WO1999031051A1/en active IP Right Grant
- 1998-12-11 US US09/581,340 patent/US6500866B1/en not_active Expired - Fee Related
- 1998-12-11 AT AT98959052T patent/ATE225768T1/de not_active IP Right Cessation
- 1998-12-11 AU AU14982/99A patent/AU1498299A/en not_active Abandoned
- 1998-12-11 DE DE69808669T patent/DE69808669T2/de not_active Expired - Fee Related
-
2002
- 2002-11-12 US US10/291,413 patent/US20030130354A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1999031051A1 (en) | 1999-06-24 |
AU1498299A (en) | 1999-07-05 |
DE69808669D1 (de) | 2002-11-14 |
DE69808669T2 (de) | 2003-07-31 |
US20030130354A1 (en) | 2003-07-10 |
EP1037874A1 (en) | 2000-09-27 |
JP2002508350A (ja) | 2002-03-19 |
EP1037874B1 (en) | 2002-10-09 |
ATE225768T1 (de) | 2002-10-15 |
GB9726388D0 (en) | 1998-02-11 |
US6500866B1 (en) | 2002-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0018272D0 (en) | Chemical compounds IV | |
ATE248824T1 (de) | Substituierte phenylderivate, ihre herstellung und verwendung | |
HUP9904361A2 (hu) | Izobutil-gaba és származékai alkalmazása fájdalom kezelésére | |
EP0842661A3 (en) | Atherosclerosis treatment | |
ATE159951T1 (de) | Fluorinierte 17-beta substituierte 4-aza-5-alpha- androstan-3-on derivate | |
ES2142773A1 (es) | Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida. | |
LU92263I2 (fr) | Imépitoïne et ses dérivés pharmaceutiquement acceptables (PEXION) | |
ES2185237T3 (es) | 1-(asamantil)amidinas y su utilizacion en el tratamiento de estados generalmente asociados con anomalias en la transmision glutamatergica. | |
MXPA03001081A (es) | Medicamento anti-inflamatorio. | |
DK1031556T3 (da) | 2-phenoxyanilinderivater | |
AU2116900A (en) | 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission | |
WO1999038841A8 (en) | Adamantanecarboximidamide derivatives and their use as nmda antagonists | |
IL132575A0 (en) | Benzimidazole derivative | |
PT1049672E (pt) | Derivados de azetidinocarboxamida para o tratamento de disturbios do snc | |
AU2178199A (en) | Azetidinecarboxamide derivatives for the treatment of cns disorders | |
SE9800932D0 (sv) | New compunds | |
AU2178099A (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
TW358809B (en) | Phenylamidinothiophene compound and anti-inflammatory agent containing the same | |
TW355184B (en) | Substituted thiophenylsulfonylureas and -thioureas, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
MX9706627A (es) | Derivado de tiazolidinona opticamente activo. | |
ES2076865A1 (es) | Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat). | |
MX9800925A (es) | Uso de derivados de adamantano para tratar enfermedades del oido interno. | |
CA2228393A1 (en) | Use of adamantane derivatives for treating diseases of the inner ear | |
ES2107971A1 (es) | Combinacion estabilizante. |